No Data
BioXcel Therapeutics Shares Rise After Preliminary Q2 Revenue Exceeds Estimates
BioXcel Therapeutics (BTAI) shares rose more than 5% in recent Tuesday trading after the company said it expects Q2 revenue of about $1.1 million, up about 141% from a year earlier.Analysts polled
Express News | BioXcel Therapeutics Announced Preliminary Sales Of Igalmi (Dexmedetomidine) Sublingual Film For Q2 Of Approximately $1.1M, Up Approximately 90% Quarter Over Quarter And Approximately 141% Year-over-year
Express News | BioXcel Therapeutics Inc Sees Unaudited Revenue of About $1.1 Mln for Three Months Ended June 30
Express News | BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues From Sales of Igalmi™ (Dexmedetomidine) Sublingual Film
Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Maintains $7 Price Target
Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $7 price target.
CCORF Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Maintains Target Price $7
CCORF analyst Sumant Kulkarni maintains $BioXcel Therapeutics(BTAI.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 40.2% and